Dutch market stutters in 2017
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
A lack of support from doctors, coupled with the rising influence of private-label products, plus a slow start to the cough and cold season, made the Netherlands a tough place to play for OTC firms in 2017. Matt Stewart takes a look at the latest data from IQVIA and Neprofarm.